The research progress of carbohydrate antigens and their relative molecules in tumor diagnosis

doi:10.3969/j.issn.1673-8640.2014.09.001

Abstract

Abstract:

Glycosylation changes are the common characteristics of cancer cells. Some types of glycan structures are recognized as the markers of tumor development, but the current molecules cannot regularly meet the pressing needs of tumor early diagnosis, prognosis and metastasis judgment. In recent years, a remarkable progress has been made in the yield of carbohydrate antigens(CA) and their relative molecules in tumor diagnosis. In order to serve the clinical needs better, new tumor markers of CA and their relative molecules, together with multi-parameter analysis, should be established.

Key words: Carbohydrate antigen, Tumor diagnosis, Multi-parameter analysis

CLC Number:

R446.62

GAO Feng. The research progress of carbohydrate antigens and their relative molecules in tumor diagnosis[J]. , 2014, 29(9): 873-876.

References

[1] Hareyama H, Sakuraqi N, Makinoda S, et al. Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma[J]. J Clin Pathol,1996,49(12):967-970.
[2] Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma[J]. J Hepatol,2005,43(6):1007-1012.
[3] 包永星,杨颖,赵化荣,等. 高尔基体蛋白73对早期肝癌的诊断价值及临床意义[J].中华肿瘤杂志, 2013,35(7):505-508.
[4] Xiao WK, Qi CY, Chen D, et al. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis[J]. BMC Cancer,2014, 14:104.
[5] Zhou MQ, Du Y, Liu YW, et al. Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer[J]. BMC Cancer,2013, 13:359.
[6] Markel G, Ortenberg R, Seidman R, et al. Systemic dysregulation of CEACAM1 in melanoma patients[J]. Cancer Immunol Immunother,2010,59(2):215-230.
[7] Tilki D, Singer BB, Shariat SF, et al. CEACAM1: a novel urinary marker for bladder cancer detection[J]. Eur Urol, 2010,57(4):648-654.
[8] 刘天舟,张琳,王庆芳.非小细胞肺癌患者血清CA153、CA242及CYFRA21-1水平测定[J]. 郑州大学学报(医学版),2012,47 (1):113-115.
[9] 邓小康,张才全.血清肿瘤相关糖蛋白抗原(TAG-72)测定对胃癌诊断价值的评价[J].重庆医科大学学报,1998,23 (4):349-351.
[10] Ekici S, Cerwinka WH, Duncan R, et al. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1),CD44v6 and microvessel density for prostate cancer[J]. Int J Cancer,2004,112(1): 121-129.
[11] Mima K, Beppu T, Ishiko T, et al. Preoperative serum hyaluronic acid level as a prognostic factor in patients undergoing hepatic resection for hepatocellular carcinoma[J].Br J Surg,2014,101(3):269-276.
[12] Josefsson A, Adamo H, Hammarsten P, et al. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome[J]. Am J Pathol, 2011,179(4):1961-1968.
[13] Kumar S, West DC, Ponting JM, et al. Sera of children with renal tumours contain low-molecular-mass hyaluronic acid[J]. Int J Cancer, 1989, 44(3):445-448.
[14] Lin RY, Argenta PA, Sullivan KM, et al. Urinary hyaluronic acid is a Wilms' tumor marker[J]. J Pediatr Surg, 1995,30(2):304-308.
[15] Kramer MW, Golshani R, Merseburger AS, et al. HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer[J]. Eur Urol,2010, 57(1): 86-93.
[16] Lokeshwar VB, Obek C, Pham HT, et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade[J]. J Urol, 2000,163(1):348-356.
[17] Franzmann EJ, Schroeder GL, Goodwin WJ, et al. Expression of tumor markers hyaluronic acid and hyaluronidase(HYAL1) in head and neck tumors[J]. Int J Cancer,2003,106(3): 438-445.
[18] 齐艳美,周逢强,郭辉光.胃液及血清中癌胚抗原和糖类抗原联合检测在胃癌诊断中的临床意义[J].中国医药,2011,6(Z1):9-11.
[19] 王刚.肿瘤标志物CEA、AFP、CA50、CA19-9和CA72-4在消化道恶性肿瘤诊断中的应用价值[J]. 大连:大连医科大学,2012.
[20] 孙羿,何辉,马强,等.膀胱肿瘤抗原和透明质酸等七项肿瘤标志物在膀胱肿瘤诊断中的应用价值[J].中华医学杂志,2005,85(35):2507-2512.